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Abstract
Background: Carcinoma of the breast is the second leading cause of malignant pleural effusions.
This study reports on the efficacy of mitoxantrone as a sclerosing agent in patients with breast
cancer who had a pleural effusion as a direct consequence of metastatic disease.
Patients and methods: Over a 5-year period, 114 patients with a known breast malignancy and
having recurrent symptomatic pleural effusion referred for chest tube drainage and sclerotherapy
were considered eligible. They had received no prior intrapleural therapy and had a predicted
survival of >1 month. All of them underwent pleural drainage and chemical pleurodesis with
mitoxantrone. Survival, complications and response to pleurodesis according to clinical and
radiographic criteria were recorded. The data are expressed as the mean ± standard error of the
mean (SEM) and the median. The χ2 test was used for statistical analysis. To assess the prognostic
value of Karnofsky's performance status score a Cox proportional hazards model was used.
Results: The mean age of the patients was 53.5 ± 2.1 years. Effusion occurred after 38.2 ± 6.2
months (range: 1–229 months) after the diagnosis. Ipsilateral effusion was seen in 73%, contralateral
in 20% and bilateral in 7%. Forty patients (35%) had pleural effusion as the first evidence of
recurrence. The mean volume of effusion drained was 1020 ± 125 ml and the chest tube was
removed within 5 days in 82% of patients. Side effects of chemical pleurodesis included mainly fever,
chest pain, nausea and vomiting. At 30 days 64 patients (56.3%) had a complete response (CR) and
30 patients (26.3%) partial response (PR) to pleurodesis (overall response: 82.6%). At 60 days the
overall response was 78.5% (CR:53.5%, PR: 25%). The mean survival was 15.6 ± 2 months.
Karnofsky's performance status score was found to be a statistically significant predictor. Patients
with Karnofsky's performance status score >70 had a median survival of 513 days, as opposed to a
median survival of only 63 days for patients with a Karnofsky's performance status score <30.
Conclusions: Mitoxantrone is effective in the treatment of malignant pleural effusion due to
breast carcinoma with relatively low local or systemic toxicity. Karnofsky's performance status
score at the time of pleurodesis is predictive of survival.
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Background
The discovery of malignant cells in pleural fluid and pari-
etal pleura signifies disseminated or advanced disease and
reduced life expectancy in cancer patients. Median sur-
vival following diagnosis ranges from 3 to 12 months and
depends mainly on the stage of the disease and type of
underlying malignancy. The shortest survival time is
observed in malignant effusions secondary to lung cancer
and the longest in ovarian cancer, while malignant effu-
sions due to an unknown primary have an intermediate
survival time [1]. Currently, lung cancer is the most com-
mon metastatic tumor to the pleura in men and breast
cancer in women. Together, both malignancies account
for approximately 50–65% of all malignant effusions [2].
About 7 to 11% of patients with breast carcinoma develop
a malignant pleural effusion during the course of the dis-
ease [3]. In 43% of these patients, pleural effusion is the
first symptom of metastatic disease [4].
The general approach to managing malignant effusions is
determined by symptoms, performance status of the
patient, expected survival and response of the known pri-
mary tumor to systemic treatment. Intervention options
range from observation in case of asymptomatic effusions
through simple thoracentesis to more invasive methods
such as thoracoscopy, pleuroperitoneal shunting and
pleurectomy. In patients with reasonable survival expect-
ancy and good performance status, every attempt should
be made to prevent recurrence of the effusion. Intercostal
tube drainage with instillation of a sclerosing agent,
resulting in obliteration of pleural space, is the most
widely used method to control recurrent symptomatic
malignant effusions.
The aim of this study was to evaluate the efficacy of mitox-
antrone as a sclerosing agent in patients with pleural effu-
sion as a direct consequence of metastatic breast cancer.
Patients and methods
Patients with a known breast malignancy and recurrent
symptomatic malignant pleural effusion referred to our
department for drainage and sclerotherapy between 1999
and2003 were recruited for this study.
The diagnosis of pleural carcinomatosis was established
by positive pleural fluid cytology on thoracentesis or pos-
itive pleural biopsy. Other eligibility criteria included evi-
dence of expansion of the lung after fluid drainage and
absence of bronchial obstruction and or fibrosis prevent-
ing lung expansion. Eligibility also required that the
patients had received no prior intrapleural therapy and
had a predicted survival of >1 month. Patients were ineli-
gible if they had a history of obstructive jaundice or sur-
gery within the previous month. No patient had systemic
chemotherapy immediately prior to or during the first 30-
day interval following sclerotherapy. This study was
approved by the Theagenion Cancer Research Ethics Com-
mittee and patients were included after obtaining written
informed consent.
Pretreatment assessment was performed during admis-
sion and included detailed history and physical examina-
tion, full blood count, liver biochemistry,
electrocardiogram, a pre-drainage base line posteroante-
rior and lateral chest radiograph and other imaging as
clinically indicated. The patients were assigned a Karnof-
sky's performance status (KPS) score based on the results
of history and physical examination [5,6]. The KPS score
is a reliable and validated quality of life measure, consist-
ing of a 10-point incremental scale from 0 to 100, where
lower score implies poor level of independent functioning
[5].
A chest tube (28–32 F) was inserted into the midaxillary
line through the 5th or 6th intercostal space under local
anesthesia and in some case additional intravenous ben-
zodiazepines and/or narcotics. The pleural effusion was
drained to dryness initially by gravity and followed if nec-
essary by suction from a wall-mounted suction pump
using a pressure of 20 cm H2O usually for 12–24 hours to
achieve complete drainage of the effusion and lung expan-
sion. Daily tube outputs were recorded and when drain-
age fell below 100 ml in a 24-h period, posteroanterior
and lateral chest radiographs were obtained to assure that
the fluid had been sufficiently evacuated, there were no
loculated collections and the lung had fully expanded.
Thereafter the pleurodesis was carried out.
Fifty ml of normal saline solution containing 2 mg/kg
lidocaine were infused through the chest tube. After 15
minutes, a pleurodesis solution containing a mixture of
40 mg mitoxantrone and 20 ml normal saline was infused
into the pleural cavity, after which the tube was clamped
for 2 hours, while the patients changed position (rotated
90°) every 15 minutes.
The tube then was reopened. The tube was removed if
post-sclerotherapy drainage was <100 ml per day. Post-
sclerotherapy posteroanterior and lateral chest radio-
graphs were obtained immediately after tube removal in
order to be compared with others obtained 30 and 60
days later.
The radiographic response was determined on poster-
oanterior and lateral chest radiographs by observing the
level of fluid meniscus overlying the costophrenic or ver-
tebrophrenic angles and was determined as follows: com-
plete response (CR) no reaccumulation of pleural fluid;
partial response (PR) reaccumulation of fluid withoutWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/16
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symptoms or not requiring repeat drainage above the
post-sclerotherapy level but below the original level; and
progressive disease (PD) reaccumulation to or above the
original level with symptoms and requiring repeat
drainage.
Survival was calculated from the day of diagnosis of pleu-
ral effusion to the day of death or to the last day of follow
up if alive. The data are expressed as the mean ± SEM
(standard error of the mean) and the median. The χ2 test
was used for statistical analysis. To assess the prognostic
value of KPS score a Cox proportional hazards model was
used. To facilitate interpretation of the resultant hazard
ratios, KPS score as a predictor variable was rescaled so
that 1-u change in hazard ratio corresponded to a 10-
point change in KPS score. All analyses were performed
using appropriate software (STATA® version 6.0, Stata-
Corp LP, Texas, USA).
Results
A total of 114 women were included in this study. The
mean age was 53.5 ± 2.1 years. Forty-four of the patients
(38.5%) were premenopausal at the time of diagnosis of
breast cancer and 70 (61.5%) were postmenopausal.
The interval between diagnosis of breast cancer and the
development of a subsequent pleural effusion ranged
from 1 month to 229 months (38.2 ± 6.2 months). One
patient developed malignant pleural effusion 19 years
after radical mastectomy. Sixty-eight patients (59.5%) had
an estrogen receptor positive tumor. Concerning lateral-
ity, 73% of these effusions were ipsilateral, 20% contralat-
eral and 7% bilateral.
Histology of the primary tumor was ductal carcinoma in
88 patients (77.1%), lobular carcinoms in 16 patients
(14%), undifferentiated carcinoma in 6 (5.2%) and
Paget's disease in 4 patients (3.7%). The TNM stage of pri-
mary tumor at the time of diagnosis of breast cancer is
shown in table 1. There was an increased proportion of
stages II and III.
Forty patients (35%) had pleural effusion as the first man-
ifestation of recurrent disease, whereas 74 patients (65%)
were already diagnosed as having local or distant spread
before the onset of pleural effusion. These 74 patients
with preexisting metastases showed a variable pattern of
secondary spread. Twenty nine patients had localized
breast or chest wall recurrence, 22 had bone metastases, 8
had synchronous bone, pulmonary and hepatic metas-
tases, 6 had synchronous bone and pulmonary metas-
tases, 3 had pulmonary metastases only, 1 had hepatic
metastases only and 1 had disease in contralateral breast.
The mean volume of effusion drained was 1020 ± 125 ml
(range: 350–1450 ml). Chest tube was removed within 5
days in 82% of patients (range: 2–10 days).
There were no deaths attributable to the thoracostomy
procedure. Two patients experienced vasovagal reflex dur-
ing the procedure with systemic hypotension and intense
pleuritic pain. Hypotension was treated with intravenous
fluids and the pain was controlled with narcotics. These
episodes lasted 30 and 45 minutes respectively. The two
patients recovered without incident. The most frequently
reported complications related to pleurodesis were fever,
chest pain, nausea and vomiting (Table 2).
Four patients died within one month of pleurodesis due
to rapid progression of metastatic disease. At 30 days, 110
patients were alive and 64 of these (56.3%) had a com-
plete response and 30 (26.3%) had a partial response. The
overall response to chemical pleurodesis with mitox-
antrone was 82.6%. Twenty patients (17.4%) had pro-
gressive disease and revealed reaccumulation of fluid to or
above the original level. At 60 days the overall response
was 78.5% (CR: 53.5% and PR: 25%).
There was no statistical significant difference in overall
response at 30 days between patients with estrogen
receptor positive and negative tumors (54/68 patients –
79.4% versus 40/46 patients – 86.9% respectively, χ2 test
p = 0.29). There was also no statistical significant differ-
ence in overall response at 30 days between patients
Table 1: TNM stage at the time of diagnosis in breast cancer patients who developed malignant pleural effusions
Stage (TNM) Number (%) of patients (n = 114)
I7  ( 6 . 1 % )
IIA 27 (23.6%)
IIB 34 (29.8%)
IIIA 22 (19.2%)
IIIB 17 (14.9%)
IV 7(6.1%)World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/16
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whose effusion was the first manifestation of recurrent
disease and those who already had local or distant metas-
tases (30/40 (75%) patients – versus 64/74 (86.4%)
patients – respectively, χ2 test p = 0.12).
Follow-up ranged from 14 days to 48 months with a mean
of 14 ± 1.5 months. The mean survival was 15.6 ± 2
months (median:13.7 months). KPS score was a predictor
concerning survival achieving statistical significance. The
patients who at minimum could not work, but were able
to care themselves and live at home (KPS score >70) had
a median survival of 17.1 months. Conversely the patients
whose general health had deteriorated to the point where
hospitalization was indicated (KPS score <30), had a
median survival of only 2.1 months (Cox test, p < 0.0001)
(Table 3).
Discussion
Pleurodesis from the Greek words pleura and desis (bind-
ing together), is intended to achieve a symphysis between
parietal and viscera pleura, in order to prevent accumula-
tion of either air or fluid in the pleural space [7]. In
patients with lymphoma, small cell lung cancer or germ
cell neoplasms, pleural effusions may be controlled ini-
tially by systemic therapy alone. Since malignant effu-
sions are frequently a preterminal event with a 30-day
mortality rate of 29 to 50% [8,9], treatment is directed
toward symptomatic relief with minimal discomfort,
inconvenience and cost.
In patients with metastatic breast or non-small cell lung
carcinoma (NSCLC), local palliative therapy is often
required. Local treatment options include repeated thora-
centeses, chest tube drainage with sclerotherapy, pleu-
roperitoneal shunt or pleurectomy. Repeated
thoracentesis is usually a temporary measure and carries
the risk for pneumothorax and pleural infection [10].
Inpatient drainage with large-bore tubes (28–36 F) is
effective, with variable 30-day success rates reported
between 55% and 95% [11]. For this reason, large-bore
tube thoracostomy with sclerotherapy has become the
most common palliative treatment for malignant effu-
sions. It has to be mentioned that recent studies have
shown that small drainage catheters (10 to 14 F) are as
effective as large bore chest tubes in the treatment of
malignant effusions [12]. Using imaging guidance, small
tubes can be placed into loculated collections, are well tol-
erated and have less complication rates than the larger
tubes [13].
Table 2: Complications related to chemical pleurodesis with mitoxantrone
Complications Number (%) of patients (n:114)
None 70 (61.4%)
Fever 28 (24.5%)
Chest pain 25 (21.9%)
Nausea 22 (19.2%)
Vomiting 10 (8.7%)
Diarrhea 5 (4.3%)
Alopecia 3 (2.6%)
Skin Rash 1 (0.8%)
Dyspnea 1 (0.8%)
Myelosuppression 1 (0.8%)
Subcutaneous emphysema 1 (0.8%)
Abscess at drain site 1 (0.8%)
Table 3: Relationship between Karnofsky's performance status (KPS) score and survival estimate
KPS score quartile Median survival (in months)
10–30 2.1
40–50 4.5
60 6.7
70–90 17.1
(Hazard ratio: 0.79; 95% Confidence Interval: 0.62–0.85, p value < 0.0001)World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/16
Page 5 of 7
(page number not for citation purposes)
Pleural effusion due to metastatic breast carcinoma is a
frequent phenomenon. Besides the rare direct invasion
through the chest wall, the pathogenesis of pleural
involvement in breast carcinoma is through either
lymphatic (internal mammary artery lymph node chain)
or hematogenous spread. As shown in our study pleural
effusion can occur as early as 1 month or as late as 19 years
with a median interval of 27 months. Rojato et al [14],
Raju et al [15], and Fentiman et al [16] have shown a
median lag time of 24, 22 and 41.5 months respectively.
When effusion occurs within 1 month of diagnosis of
breast cancer, one is probably dealing with stage IV dis-
ease and clinical experience has proved that these patients
have an generally poor prognosis.
Our study also confirms previous reports that TNM stages
II and III at the time of diagnosis are related to consequent
pleural effusion and pleural effusions most commonly
occur on the same side as the primary breast carcinoma
[4,13]. Fentiman and colleagues found in 99 patients with
unilateral breast tumors and pleural effusions, of these
50% of the effusions were ipsilateral, 40% contralateral
and 10% bilateral [16]. Raju and Kardinal observed ipsi-
lateral effusions in 85 of 122 patients [15].
All the available data on the survival of patients with
breast carcinoma after the onset of pleural effusion is
shown in table 4. In all of the studies, except for the study
reported by Rojato et al [14], the mean or median survival
after the onset of pleural effusion ranges from 6 to 15
months, indicating a poor prognosis for this group of
patients.
Our results also demonstrate that KPS scores are a predic-
tor that achieved statistical significance. Low score at the
time of pleurodesis is related to poor survival. These find-
ings are in accord with other authors [23-25].
Numerous sclerosing agents have been used to treat
malignant pleural effusions. Until recently, tetracycline
was the most commonly used sclerosing agent with
response rates ranging from 25 to 100% [26,27]. Because
the intravenous form of tetracycline is no longer available,
doxycycline has been proposed as an alternative.
Bleomycin has been studied extensively as a sclerosing
agent [28,29]. Intrapleural instillation is usually well tol-
erated but a few patients may report mild fever or tran-
sient nausea. Pleuritc pain and rigors are rarely reported
side effects. This relative lack of systemic toxicity is likely
due to limited absorption of bleomycin (approximately
40%) from the pleural cavity [30]. At 30 days bleomycin
has been reported to be superior to tetracycline [31].
Talc has proved to be one of the most effective sclerosing
agents for treating malignant pleural effusions. Talc causes
severe pleuritis resulting in effective pleurodesis but can
worsen dyspnea and can result in respiratory failure [32].
Other complications associated with talc pleurodesis
include fever, acute pneumonitis, granulomatous pneu-
monitis and empyema [33]. Talc is instilled either as a
slurry via chest tube or insufflated via thoracoscope.
Many other chemotherapeutic agents such as doxoru-
bicin, cisplatin and cytarabine combination, etoposide,
fluorouracil and mitomycin have been used for sclero-
therapy. In addition radioactive isotopes, Corynebacterium
parvum, interferon and recombinant interleukin-2 have
been instilled for treatment of malignant pleural disease.
Response rate have been variable and less than optimal.
Side effects are not inconsequential and thus none of
these agents have gained widespread use [34].
Mitoxantrone is a synthetic anthracenedione that has
demonstrated activity against metastatic breast cancer in
previous studies [35,36]. In addition to our previous pos-
Table 4: Survival of patients with breast carcinoma after the onset of pleural effusion.
Reference Number of patients Survival
Konikov et al [18] 37 mean 6.1 months
Anderson et al [19] 35 mean 9.5 months
Rosato et al [20] 50 mean 19 months (dead)
mean 54 months (alive)
Martini et al [21] 33 median 14 months
Chernow et al [22] 13 mean 7.3 months
Fentiman et al [23] 105 mean 15.7 months
Raju et al [24] 122 mean 9.7 months
Saisho et al [25] 21 42.5% at 1 year
16.5% at 2 years
Present study 114 mean 15.6 ± 2 months
median 13.7 monthsWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/16
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itive experience with mitoxantrone in the treatment of
malignant pleural effusions, this was the main reason for
us to choose this agent, despite the fact that it is more
expensive than others. From a pharmacological point of
view, mitoxantrone may be an especially appropriate
choice due to its higher molecular weight and polarity
since this may be an important factor in prolonging con-
tact with the pleura. The mechanism of intrapleural action
of mitoxantrone has not yet been established. Both the
inflammatory and antineoplastic activity of mitoxantrone
have been described [37,38].
Similar to the present study, in an earlier prospective
study Musch et al [39] reported a 30-day success rate of
75%. A comparative study including bleomycin and
mitoxantrone showed almost an equal 30-day response of
64% and 67% respectively [40]. Van Belle et al [41] had
an overall 30-day response of successful pleurodesis of
91% in patients with breast cancer. Morales et al [42]
treated a group of 21 patients with malignant pleural effu-
sions, with instillation of mitoxantrone with a 100%
response and no toxic effects. Only one study showed
mitoxantrone to be ineffective [43]. Our study confirmed
the majority of previous reports that mitoxantrone is an
effective agent in controlling recurrent malignant pleural
effusions. Side effects were mild and rare.
To develop new treatment plans for the management of
pleural effusions, one must consider several requirements.
First, no treatment regimen should exacerbate patients'
symptoms, since palliation is the main aim. Second, seri-
ously ill patients should not be subjected to procedures
associated with high mortality and morbidity. Third, since
about half the patients with pleural effusion will have no
other clinically apparent metastases, treatment should be
local rather than systemic. To be successful, the local treat-
ment has to be effective and given at the first sign of the
effusion, because inadequate or delayed treatment may
eliminate the possibility of any subsequent therapy being
effective, by producing loculation of the effusion.
Conclusions
Pleural effusions can have a significant impact on the
quality of life in patients with end-stage malignancy.
Breast cancer is very often related to malignant pleural
effusions during its course. Chemical pleurodesis via bed-
side thoracostomy has been shown to be effective and has
become a common therapeutic approach. Using this
approach we found mitoxantrone to be highly effective at
controlling malignant pleural effusions and decreasing
the associated symptoms of dyspnea and pain.
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